MX2015001413A - Metodo de alta eficiencia para purificar particulas similares a virus del virus del papiloma humano. - Google Patents

Metodo de alta eficiencia para purificar particulas similares a virus del virus del papiloma humano.

Info

Publication number
MX2015001413A
MX2015001413A MX2015001413A MX2015001413A MX2015001413A MX 2015001413 A MX2015001413 A MX 2015001413A MX 2015001413 A MX2015001413 A MX 2015001413A MX 2015001413 A MX2015001413 A MX 2015001413A MX 2015001413 A MX2015001413 A MX 2015001413A
Authority
MX
Mexico
Prior art keywords
particles
high efficiency
human papillomavirus
hpv
efficiency method
Prior art date
Application number
MX2015001413A
Other languages
English (en)
Other versions
MX361186B (es
Inventor
Hong-Jin Kim
Hyoung Jin Kim
Original Assignee
Hong Jin Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Jin Kim filed Critical Hong Jin Kim
Publication of MX2015001413A publication Critical patent/MX2015001413A/es
Publication of MX361186B publication Critical patent/MX361186B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona un método para purificar proteínas L1 del virus del papiloma humano (HPV) con alta pureza y alta eficiencia; de acuerdo con el método de purificación, una pureza de purificación y rendimiento de las proteínas L1 del HPV se pueden incrementar de manera considerable cuando el calentamiento/enfriamiento se forma al tratar un homogenato celular con un agente de reducción; además, las VLPs de la proteína L1 del HPV purificadas a través del método de purificación tienen una excelente antigenicidad e inmunogenicidad.
MX2015001413A 2012-07-30 2013-07-30 Metodo de alta eficiencia para purificar particulas similares a virus del virus del papiloma humano. MX361186B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120083472 2012-07-30
KR1020130085605A KR101559622B1 (ko) 2012-07-30 2013-07-19 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
PCT/KR2013/006823 WO2014021604A1 (ko) 2012-07-30 2013-07-30 인유두종바이러스 바이러스 유사입자의 고효율 정제방법

Publications (2)

Publication Number Publication Date
MX2015001413A true MX2015001413A (es) 2015-11-18
MX361186B MX361186B (es) 2018-11-29

Family

ID=50266708

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001413A MX361186B (es) 2012-07-30 2013-07-30 Metodo de alta eficiencia para purificar particulas similares a virus del virus del papiloma humano.

Country Status (11)

Country Link
US (1) US9994618B2 (es)
EP (1) EP2881401B1 (es)
JP (1) JP6014763B2 (es)
KR (1) KR101559622B1 (es)
CN (1) CN104507956B (es)
AU (1) AU2013297306B2 (es)
BR (1) BR112015002126B1 (es)
CA (1) CA2880420C (es)
CL (1) CL2015000037A1 (es)
MX (1) MX361186B (es)
WO (1) WO2014021604A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038625A2 (en) * 2014-09-11 2016-03-17 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
EA201790944A1 (ru) * 2014-12-26 2017-11-30 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
CN105176934B (zh) * 2015-10-16 2018-09-18 西南大学柑桔研究所 柑桔黄化脉明病毒长期离体保存方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
EP1700911B1 (en) 1997-09-05 2016-04-06 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
KR20010072470A (ko) 1998-08-14 2001-07-31 폴락 돈나 엘. 사람 유두종바이러스 바이러스-유사 입자의 정제방법
US6245568B1 (en) * 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
ES2325053T3 (es) 1999-12-09 2009-08-25 Medimmune, Llc Metodo in vitro para desensamblaje/reensamblaje de particulas similares a virus de papilomavirus (vlp).
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CN101153280B (zh) * 2006-09-29 2015-08-19 厦门大学 从原核生物中纯化人乳头瘤病毒晚期蛋白l1的方法
CN101139570A (zh) 2007-04-16 2008-03-12 马润林 一种hpv l1蛋白原核表达的高密度发酵方法
EP2907821B1 (en) 2007-05-29 2016-12-28 Xiamen University Method for producing a N-terminaly truncated L1 protein of human papillomavirus (HPV)
KR100959145B1 (ko) 2008-03-21 2010-05-25 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
CN102159239A (zh) 2008-07-31 2011-08-17 葛兰素史密斯克莱生物公司 针对hpv的疫苗
MX2011013566A (es) 2009-06-19 2012-06-28 Eyegene Inc Vacunas para cancer cervical.
KR101178056B1 (ko) 2011-12-19 2012-08-28 아이진 주식회사 자궁경부암 백신

Also Published As

Publication number Publication date
WO2014021604A1 (ko) 2014-02-06
MX361186B (es) 2018-11-29
JP2015524817A (ja) 2015-08-27
CN104507956B (zh) 2018-11-06
US9994618B2 (en) 2018-06-12
US20150266927A1 (en) 2015-09-24
CA2880420A1 (en) 2014-02-06
BR112015002126B1 (pt) 2022-10-04
AU2013297306A1 (en) 2015-02-05
KR20140018794A (ko) 2014-02-13
EP2881401B1 (en) 2018-04-25
EP2881401A1 (en) 2015-06-10
CA2880420C (en) 2018-02-27
EP2881401A4 (en) 2016-04-13
AU2013297306B2 (en) 2016-09-29
KR101559622B1 (ko) 2015-10-13
CL2015000037A1 (es) 2015-07-31
JP6014763B2 (ja) 2016-10-25
CN104507956A (zh) 2015-04-08
BR112015002126A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
MX2019004568A (es) Produccion mejorada de derivados de acidos grasos.
WO2014028453A3 (en) Natural killer cells and uses thereof
AR091538A1 (es) Purificacion de particulas tipo virus
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MY152971A (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MX2013001579A (es) Inhibidores del virus de la hepatitis c
WO2011159684A3 (en) Generation of induced pluripotent stem cells from small volumes of peripheral blood
MX2013001237A (es) Compuestos inhibidores del virus de la hepatitis c.
MX2007004696A (es) Metodos de purificacion viral mejorados.
MX354750B (es) PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
WO2012140127A3 (en) Method for priming of t cells
WO2011002198A3 (ko) 산성 가스 흡수 분리 시스템 및 방법
MX344815B (es) Metodo para purificar el factor estimulante de colonias de granulocitos humano a partir de e. coli recombinante.
MX2015001413A (es) Metodo de alta eficiencia para purificar particulas similares a virus del virus del papiloma humano.
NZ611531A (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
MX2014014683A (es) Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
MX2018006627A (es) Aumentar el rendimiento de particulas similares a virus en plantas.
WO2014122629A3 (en) Improved baculoviral expression system and methods of producing the same
MY155284A (en) Process for the preparation of ajoene
MX2018010346A (es) Proceso y medio de fermentacion de gas de sintesis.
IN2015DN02772A (es)
GB201008123D0 (en) Novel compounds

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: POSVAX CO., LTD.